Katie Shanahan and Bethany Weathersby Presented New Guidelines on HDFN at AABB 2025
Katie Shanahan, Research Consultant at the University of Pittsburgh, Director of Development at The Allo Hope Foundation, shared on LinkedIn:
”This weekend The Allo Hope Foundation was in San Diego at AABB!
Bethany and I presented new guidelines for the management of HDFN that will soon be published in major medical journals like JAMA and JACS.
Up until now, there have been no standardized, evidence based guidelines leading to inconsistent care and very preventable deaths.
These guidelines will save so many lives and I cannot believe that we are a part of them.
Even more importantly, I got to witness Bethany receive the AABB President’s Award for the work she has done and the countless lives she has saved.
She is one of the reasons my son Liam is alive and I couldn’t be more proud or honored to work with this warrior woman.
A huge thank you to Phil Spinella for his introduction into the AABB community and making the guidelines happen.
And also to the transfusion community and our industry partners for their engagement and passion for our patients and families.
Feeling so very grateful”

Stay updated with Hemostasis Today.
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial